Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review

Autoren

  • Mireia Pesarrodona
  • Toni Jauset
  • Zamira V. Díaz-Riascos
  • Alejandro Sánchez-Chardi
  • Marie Eve Beaulieu
  • Joaquin Seras-Franzoso
  • Laura Sánchez-García
  • Ricardo Baltà-Foix
  • Sandra Mancilla
  • Yolanda Fernández
  • Ursula Rinas
  • Simó Schwartz
  • Laura Soucek
  • Antonio Villaverde
  • Ibane Abasolo
  • Esther Vázquez

Organisationseinheiten

Externe Organisationen

  • IRB Barcelona - Institute for Research in Biomedicine
  • Vall d'Hebron Barcelona Campus Hospital
  • Universitat de Barcelona (UB)
  • Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
  • Vall d’Hebron Institute of Oncology (VHIO)
  • Universidad Autónoma de Barcelona (UAB)
  • Centros de Investigacion Biomedica en Red - CIBER
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Aufsatznummer1900849
FachzeitschriftAdvanced Science
Jahrgang6
Ausgabenummer18
Frühes Online-Datum24 Juli 2019
PublikationsstatusVeröffentlicht - 18 Sept. 2019

Abstract

Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. / Pesarrodona, Mireia; Jauset, Toni; Díaz-Riascos, Zamira V. et al.
in: Advanced Science, Jahrgang 6, Nr. 18, 1900849, 18.09.2019.

Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review

Pesarrodona, M, Jauset, T, Díaz-Riascos, ZV, Sánchez-Chardi, A, Beaulieu, ME, Seras-Franzoso, J, Sánchez-García, L, Baltà-Foix, R, Mancilla, S, Fernández, Y, Rinas, U, Schwartz, S, Soucek, L, Villaverde, A, Abasolo, I & Vázquez, E 2019, 'Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies', Advanced Science, Jg. 6, Nr. 18, 1900849. https://doi.org/10.1002/advs.201900849, https://doi.org/10.15488/5232
Pesarrodona, M., Jauset, T., Díaz-Riascos, Z. V., Sánchez-Chardi, A., Beaulieu, M. E., Seras-Franzoso, J., Sánchez-García, L., Baltà-Foix, R., Mancilla, S., Fernández, Y., Rinas, U., Schwartz, S., Soucek, L., Villaverde, A., Abasolo, I., & Vázquez, E. (2019). Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Advanced Science, 6(18), Artikel 1900849. https://doi.org/10.1002/advs.201900849, https://doi.org/10.15488/5232
Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J et al. Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Advanced Science. 2019 Sep 18;6(18):1900849. Epub 2019 Jul 24. doi: 10.1002/advs.201900849, 10.15488/5232
Pesarrodona, Mireia ; Jauset, Toni ; Díaz-Riascos, Zamira V. et al. / Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. in: Advanced Science. 2019 ; Jahrgang 6, Nr. 18.
Download
@article{b8748694f5b64d00a47c265ffcc5346c,
title = "Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies",
abstract = "Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.",
keywords = "biofabrication, cancer therapy, functional amyloids, inclusion bodies, protein drug release",
author = "Mireia Pesarrodona and Toni Jauset and D{\'i}az-Riascos, {Zamira V.} and Alejandro S{\'a}nchez-Chardi and Beaulieu, {Marie Eve} and Joaquin Seras-Franzoso and Laura S{\'a}nchez-Garc{\'i}a and Ricardo Balt{\`a}-Foix and Sandra Mancilla and Yolanda Fern{\'a}ndez and Ursula Rinas and Sim{\'o} Schwartz and Laura Soucek and Antonio Villaverde and Ibane Abasolo and Esther V{\'a}zquez",
note = "Funding information: M.P. and T.J. contributed equally to this work. This study has been supported by La Fundaci{\'o} Marat{\'o} TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigaci{\'o}n (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS “NANBIOSIS,” more specifically by the Protein Production Platform of CIBER-BBN/IBB (http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/) and the Biomaterial Processing and Nanostructuring Unit (http://www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS “NANBIOSIS,” specifically by U20/FVPR (http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-platform/). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award.",
year = "2019",
month = sep,
day = "18",
doi = "10.1002/advs.201900849",
language = "English",
volume = "6",
journal = "Advanced Science",
issn = "2198-3844",
publisher = "Wiley-VCH Verlag",
number = "18",

}

Download

TY - JOUR

T1 - Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies

AU - Pesarrodona, Mireia

AU - Jauset, Toni

AU - Díaz-Riascos, Zamira V.

AU - Sánchez-Chardi, Alejandro

AU - Beaulieu, Marie Eve

AU - Seras-Franzoso, Joaquin

AU - Sánchez-García, Laura

AU - Baltà-Foix, Ricardo

AU - Mancilla, Sandra

AU - Fernández, Yolanda

AU - Rinas, Ursula

AU - Schwartz, Simó

AU - Soucek, Laura

AU - Villaverde, Antonio

AU - Abasolo, Ibane

AU - Vázquez, Esther

N1 - Funding information: M.P. and T.J. contributed equally to this work. This study has been supported by La Fundació Marató TV3 and NanoCanTri (CIBER-BBN) to E.V. and I.A., and partially by ISCIII (PI15/00272 and PI1702242 co-founded by Fondo Europeo de Desarrollo Regional (FEDER), to E.V. and S.S., respectively), and Agencia Estatal de Investigación (AEI) and FEDER (BIO2016-76063-R, AEI/FEDER, UE), AGAUR (2017SGR-229) and CIBER-BBN (VENOM4CANCER) granted to A.V. Protein production and DLS have been partially performed by the ICTS “NANBIOSIS,” more specifically by the Protein Production Platform of CIBER-BBN/IBB (http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/) and the Biomaterial Processing and Nanostructuring Unit (http://www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/), respectively. Biodistribution and immunohistochemistry assays were performed at the ICTS “NANBIOSIS,” specifically by U20/FVPR (http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-platform/). L.S.-G. was supported by predoctoral fellowship from AGAUR (2018FI_B2_00051). L.S. was supported by the European Research Council (CoG #617473) and the Instituto de Salud Carlos III (FIS #PI16/01224). J.S.-F. was supported by an AECC post-doctoral fellowship. A.V. received an ICREA ACADEMIA award.

PY - 2019/9/18

Y1 - 2019/9/18

N2 - Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

AB - Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

KW - biofabrication

KW - cancer therapy

KW - functional amyloids

KW - inclusion bodies

KW - protein drug release

UR - http://www.scopus.com/inward/record.url?scp=85069946471&partnerID=8YFLogxK

U2 - 10.1002/advs.201900849

DO - 10.1002/advs.201900849

M3 - Article

AN - SCOPUS:85069946471

VL - 6

JO - Advanced Science

JF - Advanced Science

SN - 2198-3844

IS - 18

M1 - 1900849

ER -